Drug intelligence / Profile preview

SDN-037

Development stage: Phase 3
Lead developer: SPARC
Modality: Small Molecules
Administration: Ophthalmic

Overview

SDN-037 is a novel long-acting (twice-a-day) steroid ophthalmic formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery. It utilizes proprietary Tight Junction Modulation (TJM) technology to deliver a lower dose (0.04% w/v) with reduced frequency compared to currently marketed formulations that require administration every 4-6 hours. Unlike existing milky formulations that can cause vision blurring, SDN-037 has a clear solution enabling convenient dosing while maintaining efficacy.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SDN-037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDN-037.

Explore the full profile